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OBJECTIVES We sought to demonstrate the safety and performance of the actinomycin D-coated
Multilink-Tetra stent (Guidant Corp., Santa Clara, California) in the treatment of patients
with single de novo native coronary esions.
BACKGROUND Drug-eluting stents (DES) releasing sirolimus or paclitaxel dramatically reduce restenosis.
The anti-proliferative drug, actinomycin D, which is highly effective in reducing neointimal
proliferation in preclinical studies, was selected for clinical evaluation.
METHODS The multi-center, single-blind, three-arm ACTinomycin-eluting stent Improves Outcomes
by reducing Neointimal hyperplasia (ACTION) trial randomized 360 patients to receive a
DES (2.5 or 10 g/cm2 of actinomycin D) or metallic stent (MS). The primary end points
were major adverse cardiac events (MACE) at 30 days, diameter stenosis by angiography,
tissue effects, and neointimal volume by intravascular ultrasound (IVUS) at six months. When
early monitoring revealed an increased rate of repeat revascularization, the protocol was
amended to allow for additional follow-up for DES patients. Angiographic control of MS
patients was no longer mandatory.
RESULTS The biased selection of DES patients undergoing IVUS follow-up invalidated the interpre-
tation of the IVUS findings. The in-stent late lumen loss and that at the proximal and distal
edges were higher in both DES groups than in the MS group and resulted in higher
six-month and one-year MACE (34.8% and 43.1% vs. 13.5%), driven exclusively by target
vessel revascularization without excess death or myocardial infarction.
CONCLUSIONS The results of the ACTION trial indicate that all anti-proliferative drugs will not uniformly
show a drug class effect in the prevention of restenosis. (J Am Coll Cardiol 2004;44:
1363–7) © 2004 by the American College of Cardiology Foundationf
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Eestenosis after stent implantation remains a major limita-
ion of efficacy. Drug-eluting stents (DES) with sirolimus
1) and paclitaxel (2) have significantly reduced restenosis in
imple lesions, compared with the metallic stent (MS).
ctinomycin D affects the “S” phase of the cell cycle by
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ucleic acid inhibiting ribonucleic acid synthesis and is a
owerful inhibitor of cell proliferation (3). To create the
luting stent, actinomycin was coated onto the stainless-
teel Multilink Tetra stent in a polymer. We aimed to test
he safety and efficacy of two doses of actinomycin D
ompared with the MS.
ETHODS
tudy design. This was a prospective, randomized, parallel,
hree-arm, single-blind trial with two doses of drug com-
ared with control. The protocol was approved by the ethics
ommittees of all the participating institutions, and all
atients gave written, informed consent.
nd points. The primary safety end points included majordverse cardiac events (MACE) at 30 days and local tissue
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The ACTION Trial October 6, 2004:1363–7ffects (incomplete stent apposition, persisting dissection,
dge stenosis, and thrombus formation) at 6 months.
ACE was defined as a composite of death, myocardial
nfarction (MI) (more than three times the upper limit of
ormal creatine kinase levels), and revascularization (surgery
r percutaneous coronary intervention) attributed to the
arget site (the stented and 5-mm persistent segments).
hen target vessel (the vessel containing the target site)
evascularization was included in MACE, the composite
nd point was renamed “target vessel failure” (TVF).
The primary performance end points were the reduction
f in-stent volumetric burden assessed by intravascular
Table 1. Baseline Clinical and Angiographic C
Age (yrs)
Male gender
Previous MI
Diabetes mellitus*
Treated dyslipidemia
Treated hypertension
Current smoker
Angina pectoris by CCS class†
I
II
III
IV
Target coronary artery
LAD
RCA
LCx
Lesion type
A
B1
B2
C
Reference vessel diameter, baseline (mm)
Lesion length (mm)
MLD, baseline (mm)
Diameter stenosis, baseline (%)
There were no significant differences in the baseline clinical a
exception of diabetes (*difference [95% confidence interval] in
2.3%]; control vs. 10 g/cm2: 5.8% [12% to 1.02%])
Cardiovascular Society (CCS). In the 2.5- and 10-g group
stents, respectively. Data are presented as the mean value 
AcD  actinomycin D; DES  drug-eluting stent; LAD
coronary artery; MI  myocardial infarction; MLD  minim
Abbreviations and Acronyms
DES  drug-eluting stent
IVUS  intravascular ultrasound
MACE  major adverse cardiac events
MI  myocardial infarction
MS  metallic stent
QCA  quantitative coronary angiography
TSR  target site revascularization
TVF  target vessel failureartery.ltrasound (IVUS) and reduction of target site diameter
tenosis by quantitative coronary angiography (QCA) at six
onths.
The secondary performance end points were TVF at 6 and
2 months and angiographic binary restenosis at 6 months.
ower calculation and sample size. To detect a difference
f 6.6% in diameter stenosis and of 11.5 mm3 in intimal
yperplasia, with a significance level of 0.05 and 90% power,
10 patients would be needed in each of the three arms. A
ample size of 120 patients was chosen.
atient selection. Patients with stable angina pectoris or
ilent ischemia and a single de novo lesion in a native
oronary artery 3.0 mm and 4.0 mm in diameter that
ould be covered by an 18-mm stent were enrolled. Ran-
omization was done by a telephone allocation service.
tudy device. The three components of the investigational
evice were the Multilink Tetra stent, a polymeric coating,
nd an anti-proliferative drug—actinomycin D (3)—in two
oses (2.5 and 10 g/cm2 of metal stent surface area). The
luting profile of actinomycin D is targeted to release 80%
f drug in 28 days. Stents were 18 mm in length and 3.0,
.5, or 4.0 mm in diameter.
cteristics
S
118)
DES
AcD
2.5 g/cm2
(n  120)
AcD
10 g/cm2
(n  119)
10 61  11 60  11
78 80
38 37
15 11
58 54
49 45
23 29
4 4
34 35
21 23
14 13
44 42
40 35
16 23
7 2
21 29
64 64
8 5
.83 2.84 2.91
.3 11.6 10.7
.00 1.01 1.04
64 63
iographic characteristics between the three groups, with the
ence of diabetes—control vs. 2.5 g/cm2: 9.9% [17% to
gina was defined according to the system of the Canadian
e were seven and eight lesions receiving two actinomycin D
r percentage of patients.
t anterior descending coronary artery; LCx  left circumflex
inal diameter; MS  metallic stent; RCA  right coronaryhara
M
(n 
60 
78
41
5
53
50
30
7
34
21
15
37
42
21
7
23
66
4
2
11
1
64
nd ang
incid
. †An
s, ther
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October 6, 2004:1363–7 The ACTION TrialCA and IVUS. The QCA and IVUS analyses were
erformed as previously described (4,5). Coronary aneu-
ysms were angiographically defined as localized coronary
rtery dilation 1.5 times the reference diameter (4).
tatistical analysis. All analyses were based on the intent-
o-treat principle. For continuous variables, the mean value
SD was presented; differences between the treatment
roups were evaluated with the Student t test. Discrete
ariables were expressed as counts and percentages and were
nalyzed with the Fisher exact test. Event-free survival
imes were analyzed using the Kaplan-Meier method. Dif-
erences between the groups were compared with the use of
oth the Wilcoxon and log-rank tests.
ESULTS
atient baseline characteristics. In total, 360 patients
ere randomly assigned to receive a DES with a dose of 2.5
g/cm2 (n  120) or 10 g/cm2 (n  121) or a MS (n 
19). Three patients were de-registered because they did
ot receive either a DES or control stent. Baseline clinical
nd angiographic characteristics are presented in Table 1.
he significant difference in minimal lumen diameter after
he procedure between the MS and DES groups could not
e accounted for by procedural differences.
rocedural characteristics and clinical outcomes in the
ospital and at one month. The procedural success rate
as 99%. In-hospital MACE was confined to the four
able 2. Serial Quantitative Coronary Angiographic Analyses
MS
ngiographic follow-up 65 (55%)
n-stent
MLD, post-intervention (mm) 2.64 0.34
MLD, f/u (mm) 1.88 0.58
Late loss (mm) 0.76  0.43
Restenosis (%) 11
dges
Proximal MLD, post-intervention (mm) 2.60 0.53
Proximal MLD, f/u (mm) 2.32 0.60
Proximal late loss (mm) 0.28  0.38
Proximal restenosis (%) 3
Distal MLD, post-intervention (mm) 2.31 0.56
Distal MLD, f/u (mm) 2.23 0.53
Distal late loss (mm) 0.08  0.31
Distal restenosis (%) 2
arget site*
DS (%) 35 15
Restenosis (%) 14
essel segment
RD, f/u (mm) 2.76  0.58
DS, f/u (%) 37  13
Restenosis rate (%) 14
edian time of angiographic f/u (days) 162 53
Target site diameter stenosis was the primary performance end point in the intentio
DS  diameter stenosis; f/u  follow-up; RD  reference diameter; other abbreatients (1.1%) with non–Q-wave MI. The MACE rates at 20 days ranged from 0.8% to 2.5%, without differences
etween groups.
However, early monitoring of a subset of 39 DES
atients revealed an increased rate of target site revascular-
zation (TSR), suggesting that the investigational device
as not performing as intended. After the sponsor informed
he principal investigator and the Data Safety Monitoring
oard, the following recommendations were made: 1)
ccelerated angiographic follow-up for DES patients; 2) a
econd angiographic and clinical follow-up visit six months
ater; 3) possible re-intervention for moderate restenosis
30% DS); 4) extension of clopidogrel administration for
t least a further six months for DES patients; and 5)
ngiographic and IVUS follow-up was no longer mandatory
or MS patients, as primary performance end points could
ot be reached. Consequently, only 65 of 118 MS patients
nderwent imaging, and 101 had clinical follow-up at 6
onths.
ngiographic outcomes. The in-stent and in-lesion late
oss and restenosis rates at six months were higher in both
ES groups than in the MS group (Table 2). Aneurysm
ormation was infrequent, with two cases (3.1%) in the MS
roup and five (2.2%) in the DES groups.
linical outcomes at 12 months. At 12 months, MACE
nd TVF were higher in the DES than in the MS patients,
ainly due to increased TSR (Table 3). Of the 2 deaths, the
with a MS was sudden at 44 days, and the 1 with low-dose
ES was due to MI at 306 days. After 30 days, there were
DES
AcD
2.5 g/cm2 p Value
AcD
10 g/cm2 p Value
114 (95%) 115 (97%)
2.77 0.45 0.02 2.82  0.43 0.002
1.76 0.70 0.25 1.90  0.68 0.87
1.01 0.58 0.001 0.93  0.58 0.03
25 0.03 17 0.38
2.73 0.58 0.12 2.79  0.56 0.02
2.22 0.67 0.35 2.26  0.76 0.58
0.51 0.52 0.002 0.53  0.61 0.001
5 0.71 14 0.02
2.40 0.58 0.32 2.41  0.58 0.25
2.05 0.61 0.05 1.99  0.64 0.009
0.35 0.50 0.001 0.43 0.57 0.001
4 0.65 6 0.26
40 18 0.08 40  19 0.05
26 0.06 28 0.04
2.71 0.55 0.58 2.78  0.48 0.81
41 18 0.11 41  18 0.06
27 0.04 28 0.04
161 40 NS 160  41 NS
treat analysis.
s as in Table 1.n-to-additional non–Q-wave MIs in the low-dose and 1 in the
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The ACTION Trial October 6, 2004:1363–7igh-dose DES arm. To 1 year, there were 14 DES patients
ho had a second re-intervention, and in 2, a third
e-intervention (Fig. 1).
VUS outcomes. There was late-acquired incomplete stent
pposition in six patients in the low-dose group and seven in
Table 3. Most Severe (Hierarchical) and Total
Each Treatment Group
MS
(n  104)*
2
(
Death 1 (0.8)
Myocardial infarction
Q-wave 0
Non–Q-wave 1 (1.0)
Target site revascularization
CABG 1 (1.0)
PCI 11 (10.6)
Hierarchical MACE‡ 14 (13.5)
Event-free survival 90 (86.5)
Target vessel revascularization
(CABG and PCI)
3 (2.9)
Target vessel failure§ 17 (16.3)
Total count of events 16
*Follow-up was no longer mandatory for the MS group; there
patients in the 2.5- and 10-g/cm2 group, respectively, no
patients have been contacted and all are alive and had no othe
myocardial infarction, target site revascularization. §Includes
target vessel revascularization. Data are presented as the num
CABG  coronary artery bypass grafting; MACE  majo
abbreviations as in Table 1.
igure 1. Kaplan-Meier estimates of survival free of repeated target site rev
.5 and 10 g/cm2 stents and those who received the metallic stent. The ra
n the actinomycin stent groups (p  0.05 by both the Wilcoxon and log-r
2 2g/cm drug-eluting stent (n  120); squares  drug-coated, 10 g/cm drughe high-dose group. At variance with the angiographic
ndings, there were apparently no differences between
roups in volumetric obstruction measured by IVUS. This
iscrepancy is the result of a biased selection of DES
atients undergoing IVUS during follow-up, as demon-
nt of Cardiac Events Up to 12 Months in
DES
D
/cm2
120)†
p
Value
AcD
10 g/cm2
(n  119)†
p
Value
.8) NS 0 NS
NS 0 NS
.7) NS 4 (3.4) NS
NS 5 (4.2) NS
0.8) 0.001 41 (34.5) 0.001
3.3) 0.01 50 (42.0) 0.001
6.7) 69 (58.0)
.3) NS 1 (0.8) NS
6.7) 0.001 51 (42.9) 0.001
61
r 14 patients no follow-up was available. †For five and three
-up case report forms have been received; however, these
CE in the 12-month follow-up time frame. ‡Includes death,
, myocardial infarction, target site revascularization, and/or
) of patients.
rse events; PCI  percutaneous coronary intervention; other
rization up to 365 days among patients who received actinomycin-eluting
event-free survival was significantly higher in the control stent group than
ests). Solid circles  control (n  104); open circles  drug-coated, 2.5Cou
Ac
.5 g
n 
1 (0
0
2 (1
0
37 (3
40 (3
80 (6
4 (3
44 (3
45
fore, fo
follow
r MA
death
ber (%
r adveascula
te of
ank t-eluting stent (n  119).
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October 6, 2004:1363–7 The ACTION Trialtrated by the higher binary “vessel segment” restenosis rate
32% and 47.8%) in the DES patients who did not undergo
VUS follow-up, compared with those who did (25.8% and
3.7%) (Table 4). This biased selection invalidated inter-
retation of the IVUS findings.
ISCUSSION
his trial showed that while in-hospital and one-month
utcomes were similar in each group, by six months there
as increased restenosis, late lumen loss, and TSR in the
ES arm. Despite this increased rate of restenosis, mortal-
ty and MI rates were very low.
The safety of the polymer was demonstrated in the
orcine coronary model, where the histologic response was
imilar to MS to 180 days. Drug-eluting stents with four
oses of actinomycin D (2.5, 10, 40, and 70 g/cm2) were
valuated in preclinical studies in the porcine coronary
odel by angiography, histomorphometry, and histopathol-
gy at 28 days. At this time, all vessels were patent, and
here was marked suppression of neointimal formation
bove the stent with all doses. Neointimal thickness above
he internal elastic lamina was decreased in all dose groups
ompared with the MS control. Medial thinning and
ecrosis were observed in the high-dose groups, as was
ositive remodeling. Intimal fibrin deposition and inflam-
able 4. Incidence of Vessel Segment Restenosis in Patients
ith and Without Intravascular Ultrasound
MS
DES
AcD
2.5 g/cm2
AcD
10 g/cm2
atients with IVUS 4/39 (10.3) 23/89 (25.8) 22/93 (23.7)
atients without IVUS 5/26 (19.2) 8/25 (32.0) 11/23 (47.8)
*p  0.47 p  0.61 p  0.037
Fischer exact test. Data are presented as n/N (%).
IVUS  intravascular ultrasound; other abbreviations as in Table 1.ation were present with all doses, but most marked with
he higher doses. Based on these preclinical findings, the
wo lower doses were considered safe for further evaluation
n humans, with three months of data pending, which was
he practice for MS extended to DES at the time. This trial
as demonstrated that 28-day animal data do not provide
ufficient information to judge the safety and efficacy of
ES.
onclusions. This trial demonstrates that not all anti-
roliferative drugs are effective in the prevention of reste-
osis. It has become clear that promise in early preclinical
tudies (30 days) does not necessarily translate into clinical
ffectiveness at 6 months and that late safety animal data (90
ays) is a prerequisite for clinical investigation (6).
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